Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH study)
Alan Maisel, Yang Xue, Dirk J. Van Veldhuisen, Adriaan A. Voors, Tiny Jaarsma, Peter Pang, Javed Butler, Bertram Pitt, Paul Clopton, Rudolf A. De Boer
The aim of our study is to investigate the effect of spironolactone on 30-day outcomes in patients with acute heart failure (AHF) and the association between treatment and outcomes stratified by biomarkers. We conducted a secondary analysis of the biomarker substudy of the multicenter COACH (Co-ordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure) trial involving 534 AHF patients for 30-day mortality and HF rehospitalizations. Spironolactone therapy was initiated and terminated at the discretion of the treating physician; 30-day outcomes were compared between patients who were treated with spironolactone and those who were not. Outcomes with spironolactone therapy were explored based on N-terminal pro-B-type natriuretic peptide, ST2, galectin-3, and creatinine levels. Spironolactone was prescribed to 297 (55.6%) patients at discharge (158 new and 139 continued). There were 19 deaths and 30 HF rehospitalizations among 46 patients by 30 days. Patients discharged on spironolactone had significantly less 30-day event (hazard ratio 0.538, p = 0.039) after adjustment for multiple risk factors. Initiation of spironolactone in patients who were not on spironolactone before admission was associated with a significant reduction in event rate (hazard ratio 0.362, p = 0.027). The survival benefit of spironolactone was more prominent in patient groups with elevations of creatinine, N-terminal pro-B-type natriuretic peptide, ST2, or galectin-3. In conclusion, AHF patients who received spironolactone during hospitalization had significantly fewer 30-day mortality and HF rehospitalizations, especially in high-risk patients.
https://doi.org/10.1016/j.amjcard.2014.05.062
Brain Natriuretic Peptide
Maisel, A., Xue, Y., Van Veldhuisen, D. J., Voors, A. A., Jaarsma, T., Pang, P., ... De Boer, R. A. (2014). Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH study). The American Journal of Cardiology, 114(5), 737-742. https://doi.org/10.1016/j.amjcard.2014.05.062
Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH study). / Maisel, Alan; Xue, Yang; Van Veldhuisen, Dirk J.; Voors, Adriaan A.; Jaarsma, Tiny; Pang, Peter; Butler, Javed; Pitt, Bertram; Clopton, Paul; De Boer, Rudolf A.
In: The American Journal of Cardiology, Vol. 114, No. 5, 01.09.2014, p. 737-742.
Maisel, A, Xue, Y, Van Veldhuisen, DJ, Voors, AA, Jaarsma, T, Pang, P, Butler, J, Pitt, B, Clopton, P & De Boer, RA 2014, 'Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH study)', The American Journal of Cardiology, vol. 114, no. 5, pp. 737-742. https://doi.org/10.1016/j.amjcard.2014.05.062
Maisel A, Xue Y, Van Veldhuisen DJ, Voors AA, Jaarsma T, Pang P et al. Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH study). The American Journal of Cardiology. 2014 Sep 1;114(5):737-742. https://doi.org/10.1016/j.amjcard.2014.05.062
Maisel, Alan ; Xue, Yang ; Van Veldhuisen, Dirk J. ; Voors, Adriaan A. ; Jaarsma, Tiny ; Pang, Peter ; Butler, Javed ; Pitt, Bertram ; Clopton, Paul ; De Boer, Rudolf A. / Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH study). In: The American Journal of Cardiology. 2014 ; Vol. 114, No. 5. pp. 737-742.
@article{b761be65791c42aaaee601ed9613e251,
title = "Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH study)",
abstract = "The aim of our study is to investigate the effect of spironolactone on 30-day outcomes in patients with acute heart failure (AHF) and the association between treatment and outcomes stratified by biomarkers. We conducted a secondary analysis of the biomarker substudy of the multicenter COACH (Co-ordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure) trial involving 534 AHF patients for 30-day mortality and HF rehospitalizations. Spironolactone therapy was initiated and terminated at the discretion of the treating physician; 30-day outcomes were compared between patients who were treated with spironolactone and those who were not. Outcomes with spironolactone therapy were explored based on N-terminal pro-B-type natriuretic peptide, ST2, galectin-3, and creatinine levels. Spironolactone was prescribed to 297 (55.6{\%}) patients at discharge (158 new and 139 continued). There were 19 deaths and 30 HF rehospitalizations among 46 patients by 30 days. Patients discharged on spironolactone had significantly less 30-day event (hazard ratio 0.538, p = 0.039) after adjustment for multiple risk factors. Initiation of spironolactone in patients who were not on spironolactone before admission was associated with a significant reduction in event rate (hazard ratio 0.362, p = 0.027). The survival benefit of spironolactone was more prominent in patient groups with elevations of creatinine, N-terminal pro-B-type natriuretic peptide, ST2, or galectin-3. In conclusion, AHF patients who received spironolactone during hospitalization had significantly fewer 30-day mortality and HF rehospitalizations, especially in high-risk patients.",
author = "Alan Maisel and Yang Xue and {Van Veldhuisen}, {Dirk J.} and Voors, {Adriaan A.} and Tiny Jaarsma and Peter Pang and Javed Butler and Bertram Pitt and Paul Clopton and {De Boer}, {Rudolf A.}",
doi = "10.1016/j.amjcard.2014.05.062",
journal = "American Journal of Cardiology",
T1 - Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH study)
AU - Maisel, Alan
AU - Xue, Yang
AU - Van Veldhuisen, Dirk J.
AU - Voors, Adriaan A.
AU - Jaarsma, Tiny
AU - Pang, Peter
AU - Butler, Javed
AU - Clopton, Paul
AU - De Boer, Rudolf A.
N2 - The aim of our study is to investigate the effect of spironolactone on 30-day outcomes in patients with acute heart failure (AHF) and the association between treatment and outcomes stratified by biomarkers. We conducted a secondary analysis of the biomarker substudy of the multicenter COACH (Co-ordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure) trial involving 534 AHF patients for 30-day mortality and HF rehospitalizations. Spironolactone therapy was initiated and terminated at the discretion of the treating physician; 30-day outcomes were compared between patients who were treated with spironolactone and those who were not. Outcomes with spironolactone therapy were explored based on N-terminal pro-B-type natriuretic peptide, ST2, galectin-3, and creatinine levels. Spironolactone was prescribed to 297 (55.6%) patients at discharge (158 new and 139 continued). There were 19 deaths and 30 HF rehospitalizations among 46 patients by 30 days. Patients discharged on spironolactone had significantly less 30-day event (hazard ratio 0.538, p = 0.039) after adjustment for multiple risk factors. Initiation of spironolactone in patients who were not on spironolactone before admission was associated with a significant reduction in event rate (hazard ratio 0.362, p = 0.027). The survival benefit of spironolactone was more prominent in patient groups with elevations of creatinine, N-terminal pro-B-type natriuretic peptide, ST2, or galectin-3. In conclusion, AHF patients who received spironolactone during hospitalization had significantly fewer 30-day mortality and HF rehospitalizations, especially in high-risk patients.
AB - The aim of our study is to investigate the effect of spironolactone on 30-day outcomes in patients with acute heart failure (AHF) and the association between treatment and outcomes stratified by biomarkers. We conducted a secondary analysis of the biomarker substudy of the multicenter COACH (Co-ordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure) trial involving 534 AHF patients for 30-day mortality and HF rehospitalizations. Spironolactone therapy was initiated and terminated at the discretion of the treating physician; 30-day outcomes were compared between patients who were treated with spironolactone and those who were not. Outcomes with spironolactone therapy were explored based on N-terminal pro-B-type natriuretic peptide, ST2, galectin-3, and creatinine levels. Spironolactone was prescribed to 297 (55.6%) patients at discharge (158 new and 139 continued). There were 19 deaths and 30 HF rehospitalizations among 46 patients by 30 days. Patients discharged on spironolactone had significantly less 30-day event (hazard ratio 0.538, p = 0.039) after adjustment for multiple risk factors. Initiation of spironolactone in patients who were not on spironolactone before admission was associated with a significant reduction in event rate (hazard ratio 0.362, p = 0.027). The survival benefit of spironolactone was more prominent in patient groups with elevations of creatinine, N-terminal pro-B-type natriuretic peptide, ST2, or galectin-3. In conclusion, AHF patients who received spironolactone during hospitalization had significantly fewer 30-day mortality and HF rehospitalizations, especially in high-risk patients.
U2 - 10.1016/j.amjcard.2014.05.062
DO - 10.1016/j.amjcard.2014.05.062
JO - American Journal of Cardiology
JF - American Journal of Cardiology
10.1016/j.amjcard.2014.05.062